Aurobindo Pharma’s arm gets 'Official Action Indicated' classification for Bhiwadi facility

06 Aug 2024 Evaluate

The United States Food and Drug Administration (USFDA) has determined the inspection classification status of Unit II, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, situated at Bhiwadi, Alwar, Rajasthan, as ‘Official Action Indicated (OAI)’.

The USFDA had conducted an inspection from April 25 to May 3, 2024 at this facility. The company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1220.20 -27.70 (-2.22%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.